Eylea® HD (aflibercept) – New formulation approval
August 18, 2023 - Regeneron announced the FDA approval of Eylea HD (aflibercept), for the treatment of:
- Neovascular (Wet) age-related macular degeneration (nAMD)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR).
Download PDF
